Revvity (RVTY) Dropped, What Is Behind the Latest Attention?

Revvity (RVTY) just moved to expand its Life Sciences reach by agreeing to acquire France based Human Cell Design and its human pancreatic beta cell models for metabolic disease research and drug screening.

Revvity’s share price has eased in the very short term, with a 1-day share price return of 2.54% down and a 7-day share price return of 5.41% down. However, the 30-day and 90-day share price returns of 6.75% and 22.00% signal firm positive momentum, and a 1-year total shareholder return of 50.54% underlines how strong the longer term ride has been despite a 5-year total shareholder return that is 32.92% lower.

Scan beyond Revvity and this acquisition by reviewing a hand picked 17 high quality undiscovered gems in health and life sciences that could be building similar niche research advantages.

Revvity is clearly trying to deepen its Life Sciences moat with Human Cell Design. The real tension now is simple. Does that quality story already sit fully in the current share price, or not yet?

Most Popular Narrative: 2.3% Overvalued

Revvity closed at $123.85, a touch above the most followed fair value estimate of about $121.07. This puts every new acquisition decision under the microscope.

Ongoing shift in product mix toward higher-margin, software-enabled and consumables-driven offerings (e.g., SaaS Signals, reagents, new IDS i20 platform), along with structural cost actions, are expected to materially expand operating and net margins, with 2026 set to start at a higher 28% operating margin baseline.

Read the complete narrative. Read the complete narrative.

Want to see what sits behind that margin reset and fair value math? The narrative leans heavily on compounding earnings power and a very specific future profit multiple. Curious how those building blocks fit together around Revvity and its Life Sciences push.

Result: Fair Value of $121.07 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

Still, if regulatory changes keep compressing diagnostics pricing or academic and government funding stays soft, the bullish Revvity margin reset story could easily stall.

Find out about the key risks to this Revvity narrative.

Another View: Our DCF Says Undervalued

The analyst narrative pins Revvity at about 2.3% above its fair value, yet the SWS DCF model points in the opposite direction. On that cash flow view, RVTY at $123.85 trades roughly 7.5% below an estimated value of $133.85, which frames the stock as undervalued instead of slightly rich. Which lens do you trust more: earnings multiples or long term cash generation?

For anyone weighing those two signals, it helps to see exactly how the SWS DCF model gets to that $133.85 number, step by step. Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Revvity for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 31 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed messages on Revvity so far and still on the fence about what it all means for you. Move quickly, test the numbers against your own expectations, and pressure test both the upside and the downside with the 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond Revvity?

If Revvity has your attention, do not stop there. Use the same energy on a wider watchlist and give yourself more than one way to win.

• Target potential mispricing early by reviewing a hand picked 31 high quality undervalued stocks that may trade below what their cash flows and balance sheets suggest.
• Build a steadier income stream by scanning a curated 6 dividend fortresses that focus on payouts above 5% with robust financial backing.
• Protect your downside first by assessing a focused 10 resilient stocks with low risk scores where resilient business models and cleaner balance sheets are the main filter.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com